Patents Examined by Patrick T. Lewis
  • Patent number: 10806747
    Abstract: Methods of treating infection including sepsis through modulation of a P2X receptor are provided.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: October 20, 2020
    Assignee: Rutgers, The State University of New Jersey
    Inventor: Gyorgy Hasko
  • Patent number: 10793852
    Abstract: A data storage medium is disclosed comprising a dried product formed by drying a salt solution dried together with artificially synthesized DNA molecules encoding digital information. The cation in the salt may be calcium, magnesium, lanthanum, or another cation. The anion in the salt may be chloride, phosphate, or another anion. The DNA is protected from degradation by drying with the salt. Stored DNA may be freed from the salt for sequencing or other analysis by mixing the dried product with a chelator. The dry product formed from DNA and a salt may contain more than 30% DNA by weight and degrade at rates that are less than a third of rate at which untreated DNA degrades.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: October 6, 2020
    Assignee: Microsoft Technology Licensing, LLC
    Inventors: Karin Strauss, Weida Chen, Robert Grass, Alexander Xavier Christof Kohll, Bichlien Hoang Nguyen
  • Patent number: 10780105
    Abstract: Disclosed herein are nucleosides, nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a Filoviridae virus infection with one or more nucleosides and/or nucleotide analogs.
    Type: Grant
    Filed: August 20, 2018
    Date of Patent: September 22, 2020
    Assignee: Janssen Biopharma, Inc.
    Inventors: Lawrence M. Blatt, Leonid Beigelman, Natalia Dyatkina, Julian Alexander Symons, David Bernard Smith
  • Patent number: 10766919
    Abstract: A class of polycyclic compounds of general formula (I), of general formula (I?), or of general formula (I?), wherein Base1, Base2, Y, Ya, Xa, Xa1, Xb, Xb1, Xc, Xc1, Xd, Xd1, R1, R1a, R2, R2a, R3, R4, R4a, R5, R6, R6a, R7, R7a, R8, and R8a are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds.
    Type: Grant
    Filed: February 1, 2018
    Date of Patent: September 8, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michael D. Altman, Brian Andresen, Wonsuk Chang, Matthew Lloyd Childers, Jared N. Cumming, Andrew Marc Haidle, Timothy J. Henderson, James P. Jewell, Rui Liang, Jongwon Lim, Hong Liu, Min Lu, Alan B. Northrup, Ryan D. Otte, Tony Siu, Benjamin Wesley Trotter, Quang T. Truong, Shawn P. Walsh, Kake Zhao
  • Patent number: 10759825
    Abstract: A class of polycyclic compounds of general formula (I), of general formula (I?), or of general formula (I?), wherein Base1, Base2, Y, Ya, Xa, Xa1, Xb, Xb1, Xc, Xc1, Xd, Xd1, R1, R1a, R2, R2a, R3, R4, R4a, R5, R6, R6a, R7, R7a, R8, and R8a are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds.
    Type: Grant
    Filed: February 1, 2018
    Date of Patent: September 1, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michael D. Altman, Brian Andresen, Wonsuk Chang, Matthew Lloyd Childers, Jared N. Cumming, James P. Jewell, Jongwon Lim, Alan B. Northrup, Ryan D. Otte, Benjamin Wesley Trotter, Quang T. Truong, Shawn P. Walsh, Kake Zhao
  • Patent number: 10751419
    Abstract: Provided herein are improved methods for the synthesis of reactive conjugate clusters and intermediates used in such methods. In particular, improvements are provided that enhance the synthesis of reactive conjugate clusters by reducing the number of synthetic steps required. The reactive conjugate clusters prepared using the improved methods don't include any transacylation impurities that are formed using existing methods. The improved methods also provide an increase in overall yield and a cost benefit over existing methods.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: August 25, 2020
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Michael T. Migawa, Jinghua Yu, W. Brad Wan, Sayten P. Patel, Guillermo Vasquez, Garth A. Kinberger, Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
  • Patent number: 10744104
    Abstract: In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, and Z are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: August 18, 2020
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Adam D. Hughes, Erik Fenster, Melissa Fleury, Roland Gendron, Edmund J. Moran
  • Patent number: 10745434
    Abstract: The present invention relates to a uridine phosphoramide prodrug, the preparation method therefor, and the medicinal uses thereof. The prodrug of the present invention is a chemical compound as shown in formula I, an optical isomer thereof or a pharmaceutically acceptable salt thereof. The prodrug of the present invention further comprises a solvate of the chemical compound shown in formula I, of an optical isomer thereof or of a pharmaceutically acceptable salt thereof. The prodrug of the present invention can treat viral infectious diseases, particularly hepatitis C viral infectious diseases.
    Type: Grant
    Filed: March 22, 2017
    Date of Patent: August 18, 2020
    Assignee: JIANGSU TASLY DIYI PHARMACEUTICAL CO., LTD.
    Inventors: Guocheng Wang, Huimin Wu
  • Patent number: 10745728
    Abstract: This invention relates to the use of analogs of purines that have two tautomeric forms, one formally complementary to thymidine, the other formally complementary to cytidine, and analogs of pyrimidines that have two tautomeric forms, one formally complementary to guanosine, the other formally complementary to adenosine. These uses include the polymerase chain reaction amplification of targets having polymorphisms in primer binding sites and ligation.
    Type: Grant
    Filed: August 27, 2018
    Date of Patent: August 18, 2020
    Inventors: Steven A Benner, Hyo-Joong Kim, Zunyi Yang
  • Patent number: 10738059
    Abstract: Biologically active compounds that can be used as photosensitizers for diagnostic and therapeutic applications, particularly for PDT of cancer, infections and other hyperproliferative diseases, fluorescence diagnosis and PDT treatment of a non-tumorous indication such as arthritis, inflammatory diseases, viral or bacterial infections, dermatological, ophthalmological or urological disorders are provided as well as providing methods to obtain them in pharmaceutical quality. In addition, conjugates are provided in which these photosensitizers are attached to water-soluble polymers via cleavable linkers that can be cleaved in the body under specific conditions. Another embodiment consists of formulating the desired tetrapyrrole photosensitizer into a pharmaceutical formulation to be injected into the body avoiding undesirable effects like solubility problems or delayed pharmacokinetics of the tetrapyrrole systems.
    Type: Grant
    Filed: February 27, 2017
    Date of Patent: August 11, 2020
    Assignee: Biolitec Unternehmensbeteiligungs II AG
    Inventors: Michael Staegemann, Rainer Haag, Arno Wiehe, Susanna Graefe, Burkhard Gitter, Volker Albrecht
  • Patent number: 10738134
    Abstract: Methods for the cross-metathesis of polysaccharides with one or more olefin-terminated side chains and cross-metathesized products are described. In an exemplary embodiment, a method for the synthesis of cellulose ?-carboxyesters via olefin cross-metathesis is described. Conditions of the reactions were relatively mild and the olefin-substituted polysaccharides and the appropriate monomeric olefin partners appear to follow Grubbs rules as summarized herein. The compounds and methods may be useful for structure-property studies, particularly those aimed at developing polymers for drug delivery, such as for controlled-release drug delivery systems, controlled-release coatings, increasing bioavailability of drugs, and maintaining drug supersaturation in the GI tract.
    Type: Grant
    Filed: September 26, 2014
    Date of Patent: August 11, 2020
    Assignee: Virginia Tech Intellectual Properties, Inc.
    Inventors: Kevin J. Edgar, Xiangtao Meng, John Matson
  • Patent number: 10736913
    Abstract: Disclosed are formulations for the treatment of cancer including inosine or a related compound in combination with an immune checkpoint inhibitor including but not limited to immune checkpoint inhibitor binding agents (including anti-CTLA4, anti-PD1, anti-LAG-3, anti-TIM-3, anti-TIGIT, anti-CD47, anti-VISTA, and anti-PD-L1), and optionally also including a reinforcing agent to boost immune response, including CAR-T, CAR-NK, tumor vaccine, oncolytic virus vaccine, TLR7/8 agonist, anti-CD47 or IL-2 receptor agonist, and optionally also including other pharmacologically immune-boosting active agents.
    Type: Grant
    Filed: March 18, 2020
    Date of Patent: August 11, 2020
    Assignee: IMMUNOSPARKLE BIOSCIENCE LLC
    Inventors: Xiangliang Yuan, Baokun He
  • Patent number: 10738074
    Abstract: A class of polycyclic compounds of general formula (II), of general formula (II?), or of general formula (II?), wherein Base1, Base2, Y, Ya, Xa, Xa1, Xb, Xb1, Xc, Xc1, Xd, Xd1, R1, R1a, R2, R2a, R3a, R4, R4a, R5, R6, R6a, R7, R7a, R8, and R8a are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds.
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: August 11, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michael D. Altman, Brian Andresen, Wonsuk Chang, Matthew Lloyd Childers, Jared N. Cumming, Andrew Marc Haidle, Timothy J. Henderson, James P. Jewell, Min Lu, Alan B. Northrup, Ryan D. Otte, Tony Siu, Benjamin Wesley Trotter, Quang T. Truong
  • Patent number: 10718029
    Abstract: The present invention relates to the field of medicine and biology. It concerns a new test for screening and therapeutic follow-up in oncology. More particularly, it relates to diagnostic and/or therapeutic tests in oncology and on neurodegenerative diseases. Molecular targeting by peptide vectors and antibodies or by small interfering RNAs (siRNAs) opens a new concept of interdependence for diagnostic and therapeutic tools.
    Type: Grant
    Filed: November 15, 2017
    Date of Patent: July 21, 2020
    Inventor: Laurence Faure
  • Patent number: 10717755
    Abstract: Disclosed are co-crystal forms of N-(2-(5-(((2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetra-hydro-2H-pyran-2-yl)oxy)-3?-fluoro-[1,1?-biphenyl]-2-yl)ethyl)-acetamide and L-proline or D-proline, their pharmaceutical compositions, processes of manufacture, and methods of use for treating neurodegenerative disorders such as diabetic peripheral neuropathy.
    Type: Grant
    Filed: February 1, 2019
    Date of Patent: July 21, 2020
    Assignee: Reata Pharmaceuticals, Inc.
    Inventors: Xin Jiang, John Allen Walling, Melanie J. Bevill, Christopher S. Seadeek, Jared P. Smit
  • Patent number: 10703773
    Abstract: The present invention aims to provide a novel glycosyl hesperetin, which is significantly reduced in miscellaneous tastes characteristic of conventional products containing glycosyl hesperetin, and a method for producing the same and uses thereof; and the objects are solved by providing a glycosyl hesperetin which comprises glycosyl hesperetin in an amount of 90% or more by mass but less than 100% by mass, on a dry solid basis, but it does not substantially contain furfural, and a method for producing the same and uses thereof.
    Type: Grant
    Filed: March 3, 2015
    Date of Patent: July 7, 2020
    Assignee: HAYASHIBARA CO. LTD.
    Inventors: Mitsuyuki Kambe, Koichi Nishi, Akira Kawashima, Akiko Yasuda, Hitoshi Mitsuzumi, Toshio Ariyasu
  • Patent number: 10703772
    Abstract: The present invention relates to novel, improved processes for the preparation of sodium glucose co-transporter 2 (SGLT-2) inhibitors and novel intermediates thereof. More particularly, the present invention relates to a novel, improved process for the preparation of gliflozin compounds such as empagliflozin and dapagliflozin, intermediates thereof. The product obtained from the processes of present invention may be amorphous or crystalline, or in the form of amorphous/crystalline solid dispersions/solutions with pharmaceutically acceptable polymers and preparation process thereof. Also, the products obtained from the present invention may be used for the preparation of medicaments for the prevention and/or treatment of diseases and conditions associated with SGLT-2 inhibition.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: July 7, 2020
    Assignee: Emmennar Pharma Private Limited
    Inventors: Maha Vishnu Mundla, Sridhar Malyala, Chandra Prakash Narani, Laxmi Narasimha Varaprasad Chintaginjala, Suresh Kumar Gunukula, Bala Yellaiah Chittiboyina, Prabhakar Bellam, Hemalatha Reddy Samireddy, Sowmya Dantham, Prasad Vure, Pooja Kale
  • Patent number: 10696708
    Abstract: Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection, with a nucleoside, a nucleotide and an analog thereof.
    Type: Grant
    Filed: February 13, 2018
    Date of Patent: June 30, 2020
    Assignee: Janssen BioPharma, Inc.
    Inventors: Natalia Dyatkina, Guangyi Wang, Leonid Beigelman, Vivek Kumar Rajwanshi
  • Patent number: 10696751
    Abstract: Provided are a solid preparation comprising an alkyl cellulose which provides excellent moldability and disintegrability even in a small amount of the alkyl cellulose, and a production method therefor. Specifically, provided are a solid preparation having an alkyl cellulose having a specific surface area by BET method of 0.5 to 10.0 m2/g and a dissolution start temperature of 5 to 27° C.; and a method for producing a solid preparation having the steps of: mixing a cellulose pulp and a first alkali metal hydroxide solution with stirring to obtain alkali cellulose, reacting the alkali cellulose with an alkylating agent to obtain a first reaction mixture, mixing the first reaction mixture and a second alkali metal hydroxide solution with stirring and without further addition of any alkylating agent to obtain a second reaction mixture, and pulverizing an alkyl cellulose isolated from the second reaction mixture to obtain an alkyl cellulose.
    Type: Grant
    Filed: March 6, 2017
    Date of Patent: June 30, 2020
    Assignee: SHIN-ETSU CHEMICAL CO., LTD.
    Inventors: Takuya Yokosawa, Naosuke Maruyama, Akira Kitamura
  • Patent number: 10695319
    Abstract: Provided are compounds generated by conjugation of triptolide with glucose to form glucose-triptolide conjugates, provides compounds with effective anti-proliferative activity and improved tolerability as compared to naturally occurring triptolide compounds.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: June 30, 2020
    Assignees: The Johns Hopkins University, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences
    Inventors: Jun Liu, Qingli He, Martin G. Pomper, Il Minn, Biao Yu, Qiaoling Wang